<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129856</url>
  </required_header>
  <id_info>
    <org_study_id>EGP-437-003</org_study_id>
    <nct_id>NCT01129856</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye</brief_title>
  <official_title>Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyegate Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyegate Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone
      phosphate formulated for ocular iontophoresis) using the EyeGateÂ® II Iontophoresis system in
      patients with dry eye.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye is the most prevalent form of ocular discomfort and irritation. Estimates range from
      20 million people in the United States being affected with mild to moderate dry eye, to as
      many as one out of every five Americans.

      EyeGate completed a single-center, randomized, double-masked, placebo-controlled Phase 2
      efficacy study in 105 subjects with mild to moderate dry eye disease, utilizing the
      Controlled Adverse Environment (CAE), a clinical model which allows for standardized
      measurement of dry eye signs and symptoms in the investigation of therapeutic agents. In this
      Phase 2 study, the improvements documented in dry eye signs and symptoms relative to the
      placebo group indicated that the ocular iontophoresis treatments with EGP-437 (dexamethasone
      phosphate formulated for ocular iontophoresis) had both a rapid onset of action and a
      long-term effectiveness.

      The Phase 3 study is intended to confirm and extend the results from the Phase 2 study,
      utilizing the CAE model. The study is designed to assess the safety and efficacy of EGP-437
      at two different dose levels: Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA and
      Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA compared to Ocular Iontophoresis with
      placebo (sodium citrate buffer solution) for the treatment of the signs and symptoms of dry
      eye.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sign: Differences in corneal fluorescein staining (inferior region, Ora Scale) Visit 1 Pre-CAE to Visit 6 compared to placebo; Symptom: Ocular discomfort at Visit 5 as compared to placebo</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sign: Corneal fluorescein staining (each region, Ora Scale); Symptom: Ocular discomfort pre- and post-CAE (Ora Scale)</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Ocular Iontophoresis EGP-437, Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocular Iontophoresis EGP-437, High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocular Iontophoresis Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone phosphate ophthalmic solution</intervention_name>
    <description>Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)</description>
    <arm_group_label>Ocular Iontophoresis EGP-437, Low Dose</arm_group_label>
    <arm_group_label>Ocular Iontophoresis EGP-437, High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium citrate buffer solution</intervention_name>
    <description>Sodium citrate buffer solution 100 mM</description>
    <arm_group_label>Ocular Iontophoresis Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a reported history of dry eye in each eye

          -  Be at least 12 years of age

          -  Demonstrate a response when exposed to the Controlled Adverse Environment model at
             Visits 1 and 2

        Exclusion Criteria:

          -  Have contraindications to the use of the test articles

          -  Have known allergy or sensitivity to the study medications or their components

          -  Have any ocular infections, active ocular inflammation, or preauricular
             lymphadenopathy

          -  Be current contact lens wearers or wear contacts during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail L Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Eye Care Group</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Maine Eye Care</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2010</study_first_posted>
  <last_update_submitted>April 25, 2011</last_update_submitted>
  <last_update_submitted_qc>April 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stephen From / President and Chief Executive Officer</name_title>
    <organization>Eyegate Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Dry eye</keyword>
  <keyword>Keratoconjunctivitis sicca</keyword>
  <keyword>Iontophoresis</keyword>
  <keyword>Ophthalmic drug delivery</keyword>
  <keyword>EGP-437</keyword>
  <keyword>Dexamethasone phosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

